COVID-19

Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine

Monica Consonni 1 · Alessandra Telesca 1 · Licia Grazzi 1 · Daniele Cazzato 2 · Giuseppe Lauria 1,3

Received: 20 October 2020 / Accepted: 5 November 2020
© The Author(s) 2020

Abstract

Objective We aimed at investigating the impact of COVID-19-related distress on patients with chronic pain, highlighting the effects of changes in individual habits and public health care reconfiguration on physical and psychological health.

Methods During the pandemic, 80 participants (25 patients with small fibre neuropathy (SFN), 42 patients with chronic migraine (CM) and 13 patients’ healthy family members (HFM)) were asked to evaluate their COVID-19 complains, changes in habits and clinical management, behaviour, mood, loneliness, quality of life (QoL), physical and mental health and coping strategies. Data were analysed by Spearman rho correlations and Mann-Whitney U tests.

Results Patients had lower QoL, lower physical health and higher catastrophizing attitude towards pain than HFM. During the pandemic, SFN patients referred greater decline in clinical symptoms, worries about contagion and discomfort for disease management changes than CM patients. In the SFN group, the higher levels of disability were associated with suffering from changes in neurologist-patient relationship. CM patients complained of agitation/anxiety that was related to feelings of loneliness, depressive mood and catastrophism.

Discussion Despite similar complains of change in habits and worries about COVID-19 pandemic, SFN and CM patients had distinct reactions. In SFN patients, pandemic distress impacted on physical health with worsening of clinical conditions, especially suffering from changes in their care. In CM patients, pandemic distress affected behaviour, mainly with psychological frailty. This suggests the need to customize public health care for patients with distinct chronic pain conditions.

Keywords COVID-19 distress · Chronic migraine · Small fibre neuropathy · Catastrophism · Quality of life · Chronic pain

Introduction

The outbreak of the new coronavirus pneumonia (COVID-19) turned to become a sudden public health crisis that strongly influenced psychological and physical health of the general population [1, 2]. Across the world, people who have potentially come into contact with the infection were asked to stay at home or in dedicated quarantine facilities. Reports concerning the psychological effects of self-isolation during past epidemics and pandemics (e.g. SARS, Ebola) confirmed that quarantined people had higher level of distress including post-traumatic stress disorder and depression [3, 4].

In Italy, the lockdown imposed between March 8th and May 3rd 2020 included restrictions of general population movement except for health care personnel and workers employed in social relevant activities and for urgent health/work needs. This stopped all elective and routine casework while healthcare providers have had to change their practice significantly. Patients with chronic diseases suffered from major burden of this sudden social reorganization due to the need of frequent access to health facilities, including in-person visits, follow ups and treatments [5, 6]. In our tertiary centre in the Lombardy region, in the most exposed area to the exponential contagion of Northern Italy, the lockdown modified dramatically our regular clinical practice of managing patients with chronic pain disorders, with increasing discomfort of those followed for chronic neuropathic pain (NP) and chronic migraine (CM) [7]. Accordingly, individuals living in Northern Italy felt the health emergency as more urgent than...
what individuals living in Central and Southern regions did [8].

Chronic pain is a common condition worldwide and is frequently associated with decreased health-related quality of life and high levels of psychological distress [9]. NP incidence is about 7–10% of the general population [10] and CM at least 2% [11]. Both these conditions are characterized by high levels of disability and impact several life aspects, such as emotion, work and social life [12–14]. These patients need to be carefully followed to arrange their therapies. Due to the lockdown measures imposed by the Italian government, NP and CM patients were forced to change their clinical management: scheduled visits were cancelled, in-person check-up appointments postponed, therapeutic sessions gone missing, while telemedicine was rapidly introduced in clinical practice. This unavoidable condition likely contributed to increase a feeling of missing and abandoning, possibly worsening pain considering its strong relationship with psychological fragility [5].

Our study aimed at evaluating whether and to what extent the changes occurring during the COVID-19 healthy emergency in the clinical status, clinical management, habits and behaviour influenced mood, loneliness, coping strategies and attitude to catastrophism in patients suffering from two different chronic pain conditions: small fibre neuropathy (SFN) and chronic migraine (CM).

Methods

Participants

Between May 2nd and June 11st 2020, patients were enrolled from the out-patient service if they had clinical and laboratory-supported diagnosis of SFN [15] and NRS > 0 at enrolment or diagnosis of CM according to international criteria [11]. They were asked to participate in the study in the context of in-person (34%) telemedicine (28%) follow-up or by phone for those whose visit was scheduled after June 15th 2020 (38%). Healthy family members (HFM) were also enrolled as healthy controls. The HFM group was included to verify the impact of COVID-19 lockdown in a pain-free healthy sample. Inclusion criteria for all participants were age > 18 years and written informed consent. Exclusion criteria included any clinical condition affecting the ability to complete self-administered psychometric scales. HFM had no diagnosis of neurological or psychiatric disorder. Informed consent was obtained from each subject. The study is in accordance with the ethical standards of our responsible institutional committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983.

Materials

Participants were asked to complete a newly developed questionnaire assessing psychological distress due to COVID-19 [16]. The COVID-19 distress questionnaire was provided by paper or digital format or administered through a phone call. The questionnaire evaluates (a) the perceived risk to contract COVID-19, (b) concerns about COVID-19, (c) changes in clinical management, (d) changes in everyday habits due to the lockdown and (e) changes in behaviour due to COVID-19 emergency. All participants were also asked to provide psychometric scales addressing mood (Hospital Anxiety and Depression Scale[17]), loneliness [18], coping strategies (pain catastrophizing scale, PCS [19]; coping strategies questionnaire, CSQ [20]) and the health status (12-Item Short Form Survey, SF-12 [21]). Additionally, patients compiled specific disease-related questionnaires assessing pain and quality of life (EUROHIS-QOL) [22]. These questionnaires have been modified in order to have the patients answering the questions in reference to a period before COVID-19 pandemic (December 2019 to January 2020) and to the study period (May–June 2020). Specifically, SFN patients were asked (i) to judge how sick they feel using a 7-point Likert scale, from 1 = normal to 7 = most sick (global impression); (ii) to evaluate, on average, how strong was the experienced pain using a 10-point Likert scales, from 0 = no pain to 10 = worst pain (Numeric Rating Scale—NRS); (iii) to specify the occurrence of the following symptoms (maximum 7): burning feet, painful cold, electric shock, tingling, sting like pins, numbness, itching, feeling of discomfort when rubbing and restless legs; (iv) to specify the occurrence of the following autonomic symptoms: sweating, diarrhoea, constipation, urinary disorders, dry eyes, dry mouth, dizziness, episodes of sudden heat and/or redness; (v) to describe the course of pain over the specified period selecting one of the following descriptions: 1 = persistent with minor fluctuations; 2 = persistent with major pain attacks; 3 = accesses of pain without substantial underlying pain; 4 = accesses of pain with constant underlying pain. CM completed the headache impact test (HIT-6) [23] considering the two time frames.

Statistical analyses

Kruskal-Wallis test was used to analyse between-group differences of demographical and psychometric variables listed in Table 1. Variables surviving Bonferroni correction (p < 0.003) were included in post hoc analyses (Mann-Whitney U test) to assay differences between patient subgroups and HFM. The Mood’s median tests for between-group differences in psychological distress due to COVID-19 pandemic measured with the newly developed questionnaire listed in Table 2, in the view of
the explorative purpose, were considered significant for p value lower than 0.01 and Mann-Whitney U post hoc tests were performed accordingly. Wilcoxon signed rank tests were used to analyse changes in clinical features and QoL within groups (Table 3). Spearman rho correlation analyses were performed to explore the relationship between chronic pain condition and mood (HADS scores), QoL, coping strategies (CSQ and PCS subscales) and physical and mental health (SF12 subscales). Analyses were performed separately for SFN and CM patients (Tables 4). Additionally, Spearman rho correlation analyses explored the association between COVID-19 pandemic impact and clinical and neuropsychological data of SFN and CM patients.

To adjust for multiple comparisons, we considered only correlations with p value ≤0.003. IBM SPSS Statistics (version 21) was used to perform analyses.

**Results**

Twenty-five SFN patients, 42 CM patients and 13 HFM volunteers participated in the study completed the COVID-19 distress questionnaire (Table 2). Twenty-three SFN patients filled out questionnaires by e-mails and two SFN patients were contacted by phone to fulfil questionnaires. None of the SFN had planned telemedicine or in-person visits between study period observation (2 May – 11 June 2020). Twenty-one CM filled out questionnaires during in-person visits, whereas 21 CM patients filled out questionnaires by e-mails. All HFM completed the questionnaires by e-mails. Patients and HFM groups had similar age and education level. As expected, based on epidemiological data, there were more females in the CM group than in the others (p < 0.001). The number of participants fulfilling scales and questionnaires are reported in Table 1 and in Table 3. Between-group analyses showed a significant difference in physical health (X² = 31.313, p < 0.001), QoL (X² = 14.778, p = 0.001) and coping strategies, namely catastrophism (CSQ: X² = 12.731, p = 0.002; PCS total score: X² = 17.425, p < 0.001; PCS helplessness: X² = 16.307; PCS rumination: X² = 12.420, p = 0.002; PCS magnification: X² = 16.922, p < 0.001). As expected, post hoc analyses documented that SFN and CM patients had lower QoL, lower scores on scale assessing physical health (SF12)
Table 2 Evaluation of the impact of COVID-19 on SFN disease management and daily life in patients with small fiber neuropathy (SFN) and chronic migraine (CM) and in healthy family members (HFM). Results are presented as median (range); mean (standard deviation).

| COVID-19 Questionnaire (A–E) | SFN patients N = 25 | CM patients N = 42 | HFM N = 13 | Group differences |
|-----------------------------|---------------------|--------------------|------------|-------------------|
| A. Perceived risk of COVID-19 |                     |                    |            |                   |
| 1 How much are you able to avoid COVID-19<sup>a</sup> | 3 (1–5); 3.37 (0.9) | 3 (1–5); 2.70 (1.2) | 3 (1–5); 3.00 (1.2) | n.s. |
| 2 # information sources on COVID-19 (max 8) | 5 (1–7); 4.58 (1.3) | 4.5 (1–8); 4.5 (1.8) | 4 (0–6); 3.76 (1.8) | n.s. |
| 3 # actions taken to avoid contagion (max 11) | 11 (6–11); 10.20 (1.4) | 11 (6–12); 10.36 (1.2) | 11 (7–11); 10.08 (1.3) | n.s. |
| B. Concern about COVID-19 |                     |                    |            |                   |
| 1 worries my illness make me more fragile in case of infection<sup>a</sup> | 4 (1–5); 3.30 (1.2) | 2 (1–5); 2.17 (1.1) | 1 (1–3); 1.14 (0.8) | < 0.001<sup>b,c,d</sup> |
| 2 Worries in the event of an infection<sup>a</sup> | 3.5 (1–5); 3.25 (1.2) | 3 (1–5); 2.92 (0.9) | 2 (1–4); 2.15 (1.1) | 0.012<sup>c</sup> |
| 3 Thinking of COVID-19<sup>a</sup> | 3 (2–5); 2.91 (0.8) | 3 (1–5); 3.12 (0.9) | 3 (1–5); 2.61 (1.0) | n.s. |
| 4 Thinking that COVID-19 can worry my family<sup>a</sup> | 4 (2–5); 3.58 (0.9) | 3 (1–5); 3.45 (1.0) | 3 (1–5); 3.00 (1.2) | n.s. |
| C. Change in disease management |                     |                    |            |                   |
| 1 Drug management change<sup>a</sup> | 1 (1–5); 1.58 (1.2) | 1 (1–4); 1.70 (1.0) | n.a. | n.s. |
| 2 Change in neurologist-patient relationship<sup>a</sup> | 2 (1–5); 2.63 (1.7) | 1 (1–5); 2.04 (1.0) | n.a. | n.s. |
| 3 Feelings of being forgotten/rejected by clinicians<sup>a</sup> | 1 (1–5); 2.52 (1.8) | 1 (1–5); 1.63 (1.3) | n.a. | < 0.001<sup>b</sup> |
| 4 Concern about negative consequences of COVID-19<sup>a</sup> | 2 (1–5); 2.50 (1.5) | 1 (1–5); 1.78 (1.1) | n.a. | < 0.001<sup>b</sup> |
| D. Change in habits due to COVID-19 state of emergency |                     |                    |            |                   |
| 1 Out-of-home habits<sup>a</sup> | 4 (1–5); 3.58 (1.1) | 4 (1–5); 3.83 (1.0) | 3 (2–5); 3.84 (1.1) | n.s. |
| 2 Household habits<sup>a</sup> | 3 (1–5); 2.87 (1.3) | 3 (1–5); 2.97 (1.2) | 3 (1–5); 2.93 (1.4) | n.s. |
| 3 Use of social networks<sup>a</sup> | 3 (1–5); 3.12 (1.3) | 3 (1–5); 2.83 (1.3) | 2 (1–5); 2.65 (1.4) | n.s. |
| 4 Work/retirement<sup>a</sup> | 4 (1–5); 3.62 (1.4) | 4 (1–5); 3.48 (1.4) | 3 (1–5); 3.15 (1.6) | n.s. |
| 5 Personal care<sup>a</sup> | 2 (1–5); 2.60 (1.4) | 2.5 (1–5); 2.61 (1.3) | 2 (1–4); 2.41 (1.4) | n.s. |
| E. Change in behaviour due to COVID-19 state of emergency |                     |                    |            |                   |
| 1 Irritable/nervous<sup>a</sup> | 1.5 (1–4); 1.66 (0.8) | 2 (1–5); 2.09 (1.0) | 2 (1–4); 2.23 (1.0) | n.s. |
| 2 Agitated/anxious<sup>a</sup> | 2 (1–5); 1.95 (1.0) | 3 (1–5); 2.21 (1.0) | 2 (1–3); 1.76 (0.7) | 0.018<sup>b</sup>; 0.013<sup>d</sup> |
| 3 Sad/depressed<sup>a</sup> | 1.5 (1–4); 1.93 (0.9) | 2 (1–5); 1.86 (0.9) | 1 (1–3); 1.38 (0.6) | n.s. |
| 4 Bored<sup>a</sup> | 2 (1–5); 2.25 (1.2) | 1.5 (1–5); 2.09 (1.1) | 2 (1–5); 2.23 (1.2) | n.s. |
| 5 Increased consumption of alcohol/cigarettes<sup>a</sup> | 1 (1–3); 1.16 (0.5) | 1 (1–5); 1.14 (0.4) | 1 (1–2); 1.07 (0.3) | n.s. |

n.s. not significant differences
<sup>a</sup>The range of responses varied from 1 (not at all) to 5 (extremely)
<sup>b</sup>SFN vs. CM
<sup>c</sup>SFN vs. HFM
<sup>d</sup>CM vs. HFM

and higher attitude towards dysfunctional coping strategies than HFM. The SFN group reported the most severe scores (Table 1). Accordingly, SFN group differed also on measures of distress related to COVID-19 pandemic (Table 2), with patients were more worried to get infected (item B1: \(X^2 = 12.550, p = 0.002\); item B2: \(X^2 = 9.829, p = 0.007\) and referring more changes in behaviour (agitation/anxiety \(X^2 = 9.332, p = 0.009\)). Post hoc analyses confirmed that SFN patients were more worried about COVID-19 infection and reported greater changes in disease management due to COVID-19 healthy emergencies than CM patients. CM patients reported greater change in behaviour and felt overall more agitated and anxious than before the pandemic (Table 2). Within-group comparisons documented worsening of clinical symptoms in SFN patients and reduced QoL in CM and HFM groups \((p < 0.05; Table 3)\).

Results of correlation analyses between clinical and psychometric variables are reported in Table 4. Briefly, in the SFN group, the greater the complaining of disease, the lower the QoL that was directly associated to anxiety and depression, and inversely related to physical health. In the CM group, adverse headache impacts were associated with
depression, anxiety and reduced global mental health and QoL. Of note, even not surviving to Bonferroni corrections, catastrophism was the only coping strategy associated with the most severe clinical manifestations both in SFN and CM. Correlation analyses also showed that the COVID-19 pandemic distress, measured with the questionnaire displayed in Table 2, was associated to psychological status and coping strategies. Specifically, in the SFN group, the greater the levels of physical disability (physical health subscale of the SF-12), the greater the suffering from changes in neurologist-patient relationship (item C2; rho = 0.712, p < 0.001). In this group, catastrophism (PCS global score) was related to changes in behaviour (sum of items of scale E) during the pandemic (rho = 0.634; p = 0.001). In the CM group, patients suffering from changes in clinical management (item C4) were those with lower mental stability (mental health subscale of the SF-12; rho = −0.475; p = 0.003). In the CM group, the greater the changes of behaviour during the pandemic (sum of items of scale E), the higher feeling of loneliness (rho = 0.481; p = 0.002) and catastrophism (PCS global score: rho = 0.528; p = 0.001). Overall, in all patients, behavioural changes due to COVID-19 lockdown (sum of items of scale E) were associated with mental health (SF-12 subscale; SFN: rho = −0.608; p = 0.002; CM: rho = −0.494; p = 0.001).

### Discussion

We sought to address the impact of the consequences of the lockdown adopted to mitigate the spread of COVID-19 and the reconfiguration of the public health care system on physical and mental health of subjects with chronic pain due to two different diseases. This approach allowed at providing information both on the condition of suffering from chronic pain and on features peculiar of each of the diseases.

The perceived risk of COVID-19 was measured considering the amount of information sources and actions taken to avoid contagion. It was similar in all participants, suggesting that they were informed about the risk of the infection and addressed the Italian government dispositions. The lockdown caused moderate to extreme changes in out-of-home habits, work and household management in half of the participants (Table 2), with a negative impact on QoL of HFM and CM patients [24] and worsening of clinical condition in SFN patients (Table 3). Patients complained also changes in clinical management, including the patient-neurologist relationship and the management of pharmacological therapy (Table 2). The stress-related psychosocial impact of the lockdown is evident and multifaceted. Similarly to our results, several recent studies documented its negative impact on QoL, habits, behaviour and mental health in patients with chronic diseases and in the general population [8, 16, 25, 26]. But we further showed that changes in habits per se did not have any apparent association with psychological well-being, whereas changes

### Table 3 Clinical data of patients with small fibre neuropathy (SFN) and chronic migraine (CM) and in healthy family members (HFM) before and during COVID-19 pandemic

|        | No. December 2019 to January 2020 | No. May–June 2020 | Sig. |
|--------|----------------------------------|-------------------|------|
| SFN    |                                  |                   |      |
| GI (min 1; max 7) | 24 | 3.96 ± 1.45 (1–6) | 24 | 4.00 ± 1.8 (2–7) | n.s. |
| NRS (min 1; max 10) | 24 | 6.45 ± 2.16 (3–10) | 23 | 7.13 ± 2.2 (3–10) | 0.013 |
| Pain symptoms (min 0; max 7) | 24 | 4.08 ± 1.8 (1–7) | 24 | 4.58 ± 1.8 (2–7) | 0.047 |
| Autonomic symptoms (min 0; max 12) | 25 | 5.52 ± 3.2 (0–11) | 25 | 5.72 ± 3.3 (0–11) | n.s. |
| Pain course (min 1; max 4) | 24 | 2.7 ± 1.0 (1–4) | 23 | 3.21 ± 0.9 (1–4) | 0.046 |
| 1. Persistent with minor fluctuations | 3 | 12% | 1 | 4% | - |
| 2. Persistent with major attacks | 9 | 38% | 6 | 25% | - |
| 3. Pain accesses without substantial underlying pain | 4 | 17% | 5 | 21% | - |
| 4. Pain accesses with constant underlying pain | 8 | 33% | 12 | 50% | - |
| QoL | 23 | 23.7 ± 5.2 | 23 | 22.39 ± 6.3 | n.s. |
| CM    |                                  |                   |      |
| HIT total score | 42 | 64.09 ± 7.0 | 42 | 62.28 ± 6.2 | n.s. |
| Little-no/some/substantial/severe | 42 | 2 / 1 / 5 / 34 | 42 | 2 / 2 / 9 / 29 | n.s. |
| QoL | 39 | 28.66 ± 4.3 | 41 | 26.82 ± 4.6 | 0.037 |
| HFM   |                                  |                   |      |
| QoL | 13 | 32.53 ± 2.7 | 13 | 29.92 ± 3.7 | 0.013 |

Data are expressed as mean ± standard deviations (range)

GC global impression, NRS Numeric Rating Scale, QoL quality of life
in behaviour (e.g. irritability, anxiety, sadness) impacted on patients’ mental health. In our clinical samples, behavioural changes due to lockdown were highly associated with a dysfunctional attitude toward negative self-statement and excessively negative beliefs about the future, namely catastrophism. This finding was in keeping with previous studies.

Table 4  Correlation analyses of clinical and neuropsychological data of patients with small fibre neuropathy (SFN; grey) and chronic migraine (CM, light grey). Correlation surviving Bonferroni correction are reported in bold

|                  | HADS-ANXIETY | HADS-DEPRESSION | PHYSICAL HEALTH | MENTAL HEALTH | LONELINESS | QoL | CSQ Distraction | CSQ Ignore | CSQ Self-determin. | CSQ Catastrophism | PCS Catastrophism |
|------------------|---------------|-----------------|----------------|---------------|------------|-----|----------------|------------|-------------------|-------------------|-----------------|
| GI               | n.s.          | n.s.            | -.573; .004    | n.s.          | n.s.       | -.548; .003 | n.s.          | n.s.       | n.s.              | n.s.              | .449; .032       |
| Autonomic symptoms | .472; .020   | n.s.            | n.s.           | n.s.          | n.s.       | n.s.    | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |
| HIT-6            | .548; <.001   | .471; .002      | -.611; .014    | -.622; <.001  | n.s.       | n.s.    | n.s.          | n.s.       | -.323; .050       | n.s.              | .305; .050       |
| HADS-ANXIETY     | -.758; <.001  | n.s.            | n.s.           | n.s.          | n.s.       | -.586; <.001 | n.s.          | n.s.       | n.s.              | n.s.              | .358; .027       |
| HADS-ANXIETY     | -.707; .001   | n.s.            | n.s.           | n.s.          | n.s.       | -.434; .006 | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |
| PHYSICAL HEALTH  | -.718; <.001  | -.694; <.001    | n.s.           | n.s.          | n.s.       | -.625; <.001 | n.s.          | n.s.       | -.390; .012       | n.s.              | -.347; .030      |
| MENTAL HEALTH (SF-12) | -.502; .017 | .496; .019      | n.s.           | n.s.          | n.s.       | -.459; .004 | n.s.          | n.s.       | -.401; .010       | -.409; .009       | .475; .003       |
| LONELINESS       | -.588; .003   | -.600; .002     | .739; <.0001   | -.527; .012   | n.s.       | n.s.    | n.s.          | n.s.       | -.497; .013       | -.780; <.001      | n.s.            |
| QoL              | -.588; .003   | -.600; .002     | .739; <.0001   | -.527; .012   | n.s.       | n.s.    | n.s.          | n.s.       | -.497; .013       | -.780; <.001      | n.s.            |
| CSQ Distraction  | n.s.          | n.s.            | n.s.           | n.s.          | n.s.       | n.s.    | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |
| CSQ Ignore       | n.s.          | n.s.            | n.s.           | n.s.          | n.s.       | n.s.    | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |
| CSQ Self-determin. | n.s.          | n.s.            | n.s.           | n.s.          | n.s.       | n.s.    | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |
| CSQ Catastrophism| .467; .022    | .425; .038      | -.562; .016    | -.462; .026   | n.s.       | n.s.    | n.s.          | n.s.       | -.486; .016       | -.680; <.001      | n.s.            |
| PCS catastrophe  | n.s.          | n.s.            | n.s.           | n.s.          | n.s.       | n.s.    | n.s.          | n.s.       | n.s.              | n.s.              | n.s.            |

No significant correlations were found for CSQ Distance subscale, CSQ Prayer subscale, Pain-relates symptoms scale and NRS; these variables are not listed in the table

CSQ coping strategies questionnaire, GI global impression, HADS Hospital Anxiety and Depression Scale, HIT-6 headache impact test-6 Items, n.s not significant (p > 0.05), PCS pain catastrophizing scale, QoL quality of life, SF-12 12-Item Short Form Survey
showing that patients with chronic pain use passive strategies and catastrophic appraisals [27]. Specifically, during pandemic, catastrophism was a distinctive appraisal of both SFN and CM patients, but it was a massively recurring attitude of the SFN group (Table 1). It is indeed acknowledged that chronic pain is a burdensome condition [13, 28] where anxiety, depression and fatigue can influence patients’ life expectations [29] and QoL [30]. Consistently, in our cohorts, low QoL in SFN and CM patients (Table 4) was associated with anxiety, depression and reduced well-being [31].

Despite similar complains of change in habits and worries about COVID-19 pandemic, SFN and CM patients had distinct reactions. More than half of CM patients were more anxious/agitated than before the pandemic. Behavioural changes affected mainly CM patients with psychological frailty showing dysfunctional attitude toward negative self-statement and excessively negative beliefs about the future, depressive mood and feeling of loneliness. This is consistent with the findings that, overall, CM affects mental health (Table 4) and it can cause depression and anxiety [32, 33]. Furthermore CM patients often have comorbid psychiatric conditions [34], but anxiety disorders particularly exacerbate pain, hypervigilance and the tendency to catastrophize in chronic conditions [32, 33]. Stress and maladaptive coping strategies were found to be major determinants of anxiety [33]. Our findings suggest that underlying dysfunctional social-cognitive mechanisms, exacerbated by COVID-19 pandemic, could have had an impact on coping reactions to chronic pain in CM. In other terms, having positive thinking attitudes and more people in our own social network increases the probability to cope better with COVID-19 pandemic distress. This is in line with the findings showing that, in people with migraine, greater openness to experiences, acceptance and behavioural disengagement are associated with lower impact and disability [35].

SFN patients complained instead of a decline in clinical conditions during pandemic (Table 2), complaining augment in the intensity and frequency of their pain. It might have been an indirect and negative consequence of the changes in clinical management. As correlation analyses suggested, in SFN, the higher the physical health measured with the SF-12, the higher the perceived changes of patients-neurological relationships. SFN patients complained more about possible negative consequence of contagion on their illness than CM patients. This in line with the view that the effect of the pandemic on pain burden may be differentially distributed across and within clinical cohorts, depending on their characteristics [5]. Consistently, SFN, more than CM, suffered from physical disability that affected QoL. (Table 4).

During the lockdown from March 8th to May 3rd, chronic pain patients have suffered from changes in clinical management [7]: missed visits, missed therapeutic sessions and rescheduling of their visits. This situation favoured a sense of missing and abandoning that increased the psychological discomfort, especially in SFN patients (Table 2). It is acknowledged that when people with chronic pain are denied assessment and treatment, their condition can worsen significantly [5]. People waiting for assessment often report severe levels of pain that interfere with their ability to function and experience deteriorating health-related QoL and increased depression [36].

Our study has some limitations. Further psychological distress instruments on COVID-19 recently developed [37, 38] could provide more detailed measures of mental health. Compared with face-to-face interviews, online-based self-reporting survey has certain limitations. Lastly, in this cross-sectional study, the survey was conducted between May and June 2020, during a relative weakening of the epidemic in Italy, and changes in QoL and mood drop off over time.

In sum, this study evaluated the impact of changes occurring during the COVID-19 healthy emergency on clinical status, clinical management, habits, behaviour, mood, QoL and coping strategies of patients with SFN and CM. We found that SFN and CM patients had similar complains of change in habits and worries about contagion, but COVID-19-related distress had distinct impact on them. It interfered with physical health in SFN patients and with mental health in CM patients.

The opportunity to investigate two different chronic pain conditions revealed that the clinical peculiarities are associated with underlining different psychological status. Even if wider samples of patients with chronic pain would have led to more generalizable results, this evidence should be taken into account and strengthens the need to customize the health care system for chronic pain conditions.

Acknowledgements Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. The authors thank all patients and patients’ family members who participated to the study.

Authors’ contributions MC had the idea of the article subject, performed statistical analyses and wrote the manuscript. AT gave substantial contribution to acquisition of data and helped in performing statistical analysis and drafting the article. DC contributed in acquiring data and in proof-reading. LG brought her expertise on the study design and gave substantial contribution to acquisition of data. GL gave substantial contributions to conception and design of the study and revising the manuscript for important intellectual content. All authors discussed the results and commented on the manuscript and approved the final article.

Funding This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Data availability Readers seeking access to the data should contact the corresponding author. Access will be granted to named individuals in accordance with ethical procedures governing the reuse of sensitive data. Specifically, to obtain the data, requestors must complete a formal data sharing agreement.
Compliance with ethical standards

Conflict of interest M.C., A.T. and D.C. declare no conflict of interest. L.G. has received advisory and lecture fees from Allergan SpA, Electrocore L.L.C., Novartis A.G., Ely Lilly none related to the current work; G.L. received advisory and lecture fees from Biogen, Vertex, CSL Behring. Astellas none related to the current work. Funders were not involved in any part of the design, execution or interpretation of this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Ethics approval The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics board of the IRCCS Foundation “Carlo Besta” Neurological Institute.

Consent to participate Informed consent was obtained from each subject enrolled in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Galea S, Merchant RM, Lurie N (2020) The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med 180:817
2. Ping W, Zheng J, Niu X, Guo C, Zhang J, Yang H, Shi Y (2020) Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic. PLoS One 15:e0234850
3. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 395:912–920
4. Hawryluck L, Gold WL, Robinson S, Pogorski S, Galea S, Styra R (2004) SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis 10:1206–1212
5. Eccleston C, Blyth FM, Dear BF, Fisher EA, Keefe FJ, Lynch ME, Palermo TM, Reid MC, Williams ACC (2020) Managing patients with chronic pain during the COVID-19 outbreak: considerations for the rapid introduction of remotely supported (eHealth) pain management services. Pain 161:889–893
6. Szerka CL, Ailani J, Barmherzig R, Klein BC, Minen MT, Harker Singh RB, Shapiro RE (2020) Migraine care in the era of COVID-19: clinical pearls and plea to insurers. Headache 60:833–842
7. Grazi L, Rizzoli P (2020) The adaptation of management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: lessons from a Tertiary Headache Center in Milan, Italy. Headache
8. Cerami C, Santì GC, Galandra C, Dodich A, Cappa SF, Vecchi T, Crespi C (2020) Covid-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline findings from the PsyCovid study. Front Psychia 11:556

9. Esteve R, Ramirez-Maestre C, Lopez-Marinez AE (2007) Adjustment to chronic pain: the role of pain acceptance, coping strategies, and pain-related cognitions. Ann Behav Med 33:179–188
10. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155:654–662
11. (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia: an international journal of headache 38:1-211
12. Kranz D, Bollinger A, Nilges P (2010) Chronic pain acceptance and affective well-being: a coping perspective. Eur J Pain 14:1021–1025
13. Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 20:41
14. McCracken LM, Eccleston C (2003) Coping or acceptance: what to do about chronic pain? Pain 105:197–204
15. Devigili G, Rinaldo S, Lombardi R, Cazzato D, Marchi M, Salvi E, Eleopra R, Lauria G (2019) Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain 142:3728–3736
16. Consonni M, Teleca A, Dalla Bella E, Bersano E, Lauria G (2020) Amyotrophic lateral sclerosis patients’ and caregivers’ distress and loneliness during COVID-19 lockdown. J Neurol
17. Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7:121–127
18. Russell DW (1996) UCLA Loneliness Scale (Version 3): reliability, validity, and factor structure. J Pers Assess 66:20–40
19. Monticone M, Baiardi P, Ferrari S, Foti C, Mugnai R, Pillarlini P, Rocca B, Vanti C (2012) Development of the Italian version of the Pain Catastrophising Scale (PCS-I): cross-cultural adaptation, factor analysis, reliability, validity and sensitivity to change. Qual Life Res 21:1045–1050
20. Monticone M, Ferrante S, Giorgi I, Galandra C, Rocca B, Foti C (2014) The 27-item coping strategies questionnaire-revised: confirmatory factor analysis, reliability and validity in Italian-speaking subjects with chronic pain. Pain Res Manag 19:153–158
21. Kodraliu G, Mosconi P, Groth N, Carmosino G, Perilli A, Gianicolo EA, Rossi C, Apolone G (2001) Subjective health status assessment: evaluation of the Italian version of the SF-12 Health Survey. Results from the MiOS Project. J Epidemiol Biostat 6:305–316
22. Schiavolin S, Quintas R, Ferroli P, Acerbi F, Brock S, Cusin A, Schiari M, Visintini S, Broggi M, Leonardo M, Raggi A (2015) Quality of life measures in Italian neurosurgical patients: validity of the EUROQOL-5D-5L index. Qual Life Res 24:441–444
23. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Schiariti M, Visintini S, Broggi M, Leonardi M, Schiavi M (2014) The 27-item coping strategies questionnaire-revised: confirmatory factor analysis, reliability and validity in Italian-speaking subjects with chronic pain. Pain Res Manag 19:153–158
24. Al-Hashel JY, Ismail II (2020) Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain 21:115
25. Chudasama YV, Gillies CL, Zaccardi F, Coles B, Davies MJ, Seidu S, Khunti K (2020) Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr 14:965–967
26. Solomon I, Constantinidou F (2020) Prevalence and predictors of anxiety and depression symptoms during the COVID-19 pandemic and compliance with precautionary measures: age and sex matter. Int J Environ Res Public Health 17

Springer
27. Higgins NC, Bailey SJ, LaChapelle DL, Harman K, Hadjistavropoulos T (2015) Coping styles, pain expressiveness, and implicit theories of chronic pain. Aust J Psychol 149:737–750
28. Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J (1997) Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 73:393–400
29. Jain R, Jain S, Raison CL, Maletic V (2011) Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators. Curr Diab Rep 11:275–284
30. Bakkers M, Faber CG, Hoeijmakers JG, Lauria G, Merkies IS (2014) Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve 49:329–336
31. Vindegaard N, Benros ME (2020) COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun 89:531–542
32. Baskin SM, Lipchik GL, Smitherman TA (2006) Mood and anxiety disorders in chronic headache. Headache 46(Suppl 3):S76–S87
33. Radat F, Mekies C, Géraud G, Valade D, Vivès E, Lucas C, Joubert JM, Lantéri-Minet M (2008) Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study. Cephalalgia 28:1115–1125
34. Baskin SM, Smitherman TA (2009) Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications. Neurol Sci 30(Suppl 1):S61–S65
35. Chan JK, Conedine NS (2014) Negative affectivity, emotion regulation, and coping in migraine and probable migraine: a New Zealand case-control study. Int J Behav Med 21:851–860
36. Lynch ME, Campbell F, Clark AJ, Dunbar MJ, Goldstein D, Peng P, Stinson J, Tupper H (2008) A systematic review of the effect of waiting for treatment for chronic pain. Pain 136:97–116
37. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH (2020) The fear of COVID-19 scale: development and initial validation. Int J Ment Heal Addict:1–9
38. Taylor S, Landry CA, Paluszek MM, Fergus TA, McKay D, Asmundson GJG (2020) Development and initial validation of the COVID Stress Scales. J Anxiety Disord 72:102232

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.